JP2017155057A5 - - Google Patents

Download PDF

Info

Publication number
JP2017155057A5
JP2017155057A5 JP2017116440A JP2017116440A JP2017155057A5 JP 2017155057 A5 JP2017155057 A5 JP 2017155057A5 JP 2017116440 A JP2017116440 A JP 2017116440A JP 2017116440 A JP2017116440 A JP 2017116440A JP 2017155057 A5 JP2017155057 A5 JP 2017155057A5
Authority
JP
Japan
Prior art keywords
parvovirus
pharmaceutical composition
composition according
cancer
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017116440A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017155057A (ja
Filing date
Publication date
Priority claimed from EP20130003664 external-priority patent/EP2829284A1/en
Application filed filed Critical
Publication of JP2017155057A publication Critical patent/JP2017155057A/ja
Publication of JP2017155057A5 publication Critical patent/JP2017155057A5/ja
Pending legal-status Critical Current

Links

JP2017116440A 2013-07-22 2017-06-14 パルボウイルスおよびBcl−2阻害剤を含有する医薬組成物 Pending JP2017155057A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13003664.3 2013-07-22
EP20130003664 EP2829284A1 (en) 2013-07-22 2013-07-22 Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016528375A Division JP6195988B2 (ja) 2013-07-22 2014-07-22 パルボウイルスにBcl−2阻害剤を併用する癌療法

Publications (2)

Publication Number Publication Date
JP2017155057A JP2017155057A (ja) 2017-09-07
JP2017155057A5 true JP2017155057A5 (enExample) 2017-11-16

Family

ID=48856486

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016528375A Active JP6195988B2 (ja) 2013-07-22 2014-07-22 パルボウイルスにBcl−2阻害剤を併用する癌療法
JP2017116440A Pending JP2017155057A (ja) 2013-07-22 2017-06-14 パルボウイルスおよびBcl−2阻害剤を含有する医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016528375A Active JP6195988B2 (ja) 2013-07-22 2014-07-22 パルボウイルスにBcl−2阻害剤を併用する癌療法

Country Status (8)

Country Link
US (2) US9889169B2 (enExample)
EP (2) EP2829284A1 (enExample)
JP (2) JP6195988B2 (enExample)
AU (1) AU2014295442B2 (enExample)
CA (1) CA2914420C (enExample)
DK (1) DK3024491T3 (enExample)
ES (1) ES2636768T3 (enExample)
WO (1) WO2015010782A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069724A1 (en) * 2015-03-19 2016-09-21 Deutsches Krebsforschungszentrum Lung cancer therapy with a rodent parvovirus
MX381890B (es) * 2016-03-15 2025-03-13 Oryzon Genomics Sa Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos
EP3429606A1 (en) * 2016-03-17 2019-01-23 Deutsches Krebsforschungszentrum Lung cancer therapy with a parvovirus
EP3225253A1 (en) 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
CN106177955B (zh) * 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
WO2018213848A1 (en) * 2017-05-19 2018-11-22 The Regents Of The University Of California Antibody chemically induced dimerizer (abcid) as molecular switches for regulating cellular therapies
EP3657172A1 (en) 2018-11-22 2020-05-27 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient´s sample
US20240041833A1 (en) 2020-12-21 2024-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pharmaceutical combination product comprising a protoparvovirus and an antiviral benzimidazole and uses thereof for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2082745T3 (da) 2007-12-28 2013-03-25 Deutsches Krebsforsch Kræftterapi med en parvovirus kombineret med kemoterapi
EP2366398A1 (en) 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor

Similar Documents

Publication Publication Date Title
JP2017155057A5 (enExample)
IL285782A (en) Compounds, compositions, and methods for treating disease
JP2020503891A5 (enExample)
WO2017189964A3 (en) Compositions for the treatment of disease
JP2016153410A5 (enExample)
MX2019000864A (es) Activadores de histona acetiltransferasa y sus composiciones y usos.
JP2016502515A5 (enExample)
NZ738018A (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
JP2014129360A5 (enExample)
EA201792487A1 (ru) Композиции гидроксипропил-бета-циклодекстринов и способы
JP2017501848A5 (enExample)
MX381224B (es) Potentes moduladores de gamma-secretasa.
JP2013541586A5 (enExample)
JP2016520594A5 (enExample)
WO2018071822A3 (en) Antibodies that bind zika virus envelope protein and uses thereof
JP2017531686A5 (enExample)
RU2016131363A (ru) ПРОИЗВОДНЫЕ АРИЛСУЛЬТАМА В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРФАННОГО РЕЦЕПТОРА γ, СВЯЗАННОГО С РЕТИНОЕВОЙ КИСЛОТОЙ
EP4484953A3 (en) Enantiomers of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine (anavex2-73) and use thereof in the treatment of alzheimer's disease and other disorders modulated by the sigma 1 receptor
HK1251998A1 (zh) 佐米曲普坦肺部给药粉
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
JP2019528267A5 (enExample)
Anton Are the Kids Al (t) right?
JP2009505991A5 (enExample)
WO2016003158A3 (ko) DX2 단백질과 p14/ARF 단백질 간의 결합을 억제하는 신규 화합물 및 상기 화합물을 유효성분으로 함유하는 암질환 치료 또는 예방용 약학조성물
EP3719010A4 (en) AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE